Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab, Ipilimumab, and CRS-207 with or without GVAX in Pancreatic Cancer
NCT03190265Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Dec 2017
- Primary completion
- Aug 2022
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GVAX pancreatic cancer vaccine in pancreatic adenocarcinoma (PDAC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Dec 2017; status: completed.
02
Drugs
GVAX pancreatic cancer vaccine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03190265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03190265.